B-30. Immunopharmacology I (cytotoxic agents, retinoids). Pharmacotherapy of autoimmune diseases. Flashcards
Cytotoxic Agents (6)
- ) Cyclophosphamide
- ) Methotrexate
- ) Lefluomide and Teriflunomide
- ) Azathioprine
- ) Mycophenolate Mofetil
When is immunosuppressive therapy used?
- ) Autoimmune disease
- ) Blocking transplant rejection
- ) Preventing GVHD in marrow transplant
How many different antigen receptors are there?
10^12, this makes it difficult to block certain antibodies/TCRs
Mechanism of action for immunosuppression?
- ) Lymphopheresis
- Removal of lymphocytes from circulation by physical methods - ) Cytotoxic agents
- To reduce lymphocyte count - ) IL-2 inhibition
- IL-2 is a lymphocyte growth factor; can either inhibit its expression or its proliferative effect - ) Cytokine inhibition
- Via biologics including mAbs or soluble receptors - ) Migration inhibition
- Decreased movement of WBCs into tissues
Cyclophosphamide MOA
Prodrug activated by CYP450 that forms phosphoramide mustard (active metabolite) and acrolein (inactive, toxic metabolite).
These metabolites alkylate the DNA (N7 of guanosine) causing cross linking inside and between DNA chains. This alkylation results in T and B cell inhibition.
Cyclophosphamide indications
- ) SLE
- ) Systemic sclerosis
- ) Vasculitis and AI hemolytic anemia
- ) Kidney disease (AI glomerulonephritis and nephrotic syndrome)
Cyclophosphamide side effects
- ) Myelosuppression (check complete blood count during treatment)
- ) Gonadal dysfunction
- Oligospermia and ovarian issues; with increased dose over long period becomes irreversible - ) Hemorrhagic cystitis
- Due to toxic acrolein metabolite; prevent with hydration and mesna treatment - ) Teratogen/Mutagen (CI in pregnancy)
- ) GI symptoms including increased risk of bladder cancer, hyponatremia via SIADH
Methotrexate (MTX) MOA
Acts as an antimetabolite to inhibit DHF reductase decreasing dTMP and DNA synthesis.
Also has anti-inflammatory effects via MTX-polyglutamates which inhibit AICAR transformylase (purine metabolism)
*MTX-polyglutamates persit in cell longer than MTX itself
Methotrexate Admin
given orally once a week; sometimes s.c. (onset takes weeks; start with steroid/NSAIDs)
Methotrexate Indication
- ) Rheumatoid arthritis (Drug of choice in moderate/severe RA)
- ) Psoriasis (other immune-related dermatological diseases including vasculitis, etc.)
- ) SLE
- ) IBD
- ) Vasculitis
- ) Dermatomyositis
Methotrexate side effects
- ) Myelosuppression
- with megaloblastic anemia; reversible with leucovorin (folinic acid) - ) Hepatotoxic
- Increased liver enzymes; also reversible with leucovorin (day after MTX admin.) - ) Pulmonary fibrosis
- restrictive leading to decreased lung volume, FEV1 and FVC, and diffusion - ) GI issues
- Including mucositis/stomatitis (with oral ulcers) and diarrhea - ) Teratogenic (via folate deficiency)
- ) Rarely nephrotoxic
Leflunomide and Teriflunomide MOA
Reversibly inhibit dihydro-orotate dehydrogenase which inhibits pyrimidine synthesis leading to decreased T-cell proliferation and decreased antibody production by B cells
Leflunomide and Teriflunomide Indication
- ) RA (leflunomide is as effective as MTX)
- ) Remitting-relapsing MS (teriflunomide used which is an active metabolite of leflunomide)
- ) Psoriatic Arthritis
Leflunomide and Teriflunomide Administration
Leflunomide given orally with loading dose (half a week to 2 weeks)
Side effects of Leflunomide and Teriflunomide
- ) Liver dysfunction (can be severe)
- ) Exanthems (widespread rash)
- ) Alopecia
- ) Mild hypertension and diarrhea